(BCDA) BioCardia, Inc. Business Model Canvas Research

BioCardia, Inc. depends on specialized medical device suppliers for Helix delivery system and Morph guides and sheaths, where tight tolerances, sterilization, packaging, and release testing shape device consistency and use safety. These partners sit at the core of performance, because small process drift can change fit, tracking, and sterility.

• Precision machining and assembly
• Sterilization and sterile packaging
• Release testing and lot consistency

BioCardia, Inc. depends on the FDA, IRBs, and ethics committees to clear study design, safety rules, and trial starts. If its therapies move toward market, coverage proof will matter for CMS and private payers that serve about 67 million Medicare members, so reimbursement data will shape adoption.

• FDA and IRBs control trial timing
• Ethics committees protect patient review
• Coverage proof drives future sales

BioCardia, Inc. must keep tight manufacturing and quality control across both cell therapy and device programs, with release testing, batch records, and validated quality systems protecting every lot. In clinical-stage biotech, one failed batch can delay a trial, so reliable GMP supply is a core value driver, not just an ops task.

• Release testing protects lot quality
• Batch docs support traceability
• GMP supply keeps trials on track

BioCardia, Inc. must keep regulatory filings, investigator packets, and trial updates moving across its clinical programs, including Phase 2 and Phase 3 work, because clean submission flow affects enrollment and review speed. Publishing peer-reviewed data also helps build trust with physicians and supports partner and licensing talks.

• Prepare filings and trial updates
• Support investigators with study materials
• Publish clinical data to build trust
• Use science to aid enrollment
• Strengthen licensing discussions

Morph deflectable guides and sheaths help BioCardia, Inc. steer catheters and reach hard anatomy more reliably, which supports procedural access and can reduce the need for third-party tools. They also widen the product base beyond therapy development and can generate standalone revenue through interventional use.

• Improve catheter navigation
• Support procedural access
• Extend the device portfolio
• Add standalone commercial value

BioCardia, Inc.’s key resources are its accumulated clinical evidence and intellectual property, which support its CardiAMP and CardiALLO programs. Its Sunnyvale, California headquarters anchors R&D and corporate work, while scientific know-how and management talent remain critical for a clinical-stage company with no commercial revenue to fund execution.

• Clinical evidence drives trial credibility
• IP protects platform value
• Sunnyvale supports R&D and ops

BioCardia, Inc.'s Helix platform delivers therapy straight into heart muscle with a penetrating helical needle, so the dose lands where it matters most. That precision is a core edge over generic catheter delivery because better intramyocardial targeting can improve cell therapy performance and reduce waste.

• Direct myocardial placement
• Helical needle penetration
• Sharper than generic catheter delivery
• Built for cell therapy accuracy

BioCardia pairs biologic therapies with dedicated delivery devices, so treatment and delivery are designed together, not bolted on. That can improve procedure control and clinical execution, and it gives partners one platform instead of separate drug and device deals.

• One integrated therapy-delivery platform
• Better procedure control and consistency
• Cleaner partner adoption, fewer interfaces

BioCardia, Inc. keeps investigators engaged by giving transparent study-data access, timely protocol updates, and direct feedback on enrollment and site performance. That matters because investigator-led research depends on steady communication to support abstracts, posters, and peer-reviewed publication of trial results.

• Transparent data access
• Timely study updates
• Feedback keeps sites active
• Supports publication and presentation

BioCardia’s customer relationships are mostly enterprise and research based, so the work centers on development milestones, device performance, and clinical endpoints rather than consumer support. That makes it a partnership-selling model, where success depends on trial progress, regulatory steps, and long sales cycles tied to hospital and research buyers.

• Enterprise and research-led
• Milestone-driven conversations
• Focus on clinical outcomes

BioCardia, Inc. uses medical affairs and key opinion leader outreach to build trust with expert physicians, which helps validate its treatment approach and shape how trial data are read. This channel also supports education and market development, and KOL input can speed future adoption once clinical evidence is strong.

• Builds physician credibility
• Helps interpret trial data
• Drives education and adoption

BioCardia, Inc. uses its corporate website and investor communications to publish pipeline updates on programs such as CardiAMP and CardiALLO, giving investors and industry stakeholders a clear view of development milestones, trial status, and regulatory progress. These public updates support transparency across a pipeline built around multiple clinical-stage programs.

• Public pipeline updates improve visibility.

• Milestones and trial status are disclosed.

• Investor communications support stakeholder trust.

Specialty cardiology and pulmonary centers are both clinical and operational customers for BioCardia, Inc., because they run trials and adopt catheter-based delivery tools for advanced heart and lung procedures. These sites matter most in complex care, where catheter therapy is often used instead of surgery and where BioCardia, Inc. can sell both procedure support and study-use systems.

• Run clinical studies.
• Adopt catheter delivery systems.
• Need advanced procedures.

BioCardia’s biopharma and research collaborators are key non-patient customers because the Company can use co-development and licensing to extend its cell therapy and delivery platform beyond direct sales. In its latest reported filings, the Company was still development-stage, so partner deals matter for reach, validation, and future revenue.

• Co-development partners
• Licensing partners
• Cell therapy and delivery tech firms
• Expand platform reach

BioCardia, Inc. must keep paying for documentation, audits, and regulatory submissions across both device and biologics work, and these costs stay high while investigational products move through FDA review. The burden shows up in ongoing R&D and quality spend, since every change, protocol update, and safety report needs controlled records and submission support.

• Ongoing FDA-facing compliance work
• Device and biologics costs both recur
• Investigational products need extra control

BioCardia, Inc. carries fixed public-company overhead from its Sunnyvale HQ, plus legal, finance, and investor-relations spend. For a small biotech, SG&A can stay heavy versus revenue, so this cost block can pressure cash use even before product sales scale.

• Sunnyvale HQ and admin costs
• Legal, finance, IR spend
• Overhead is fixed and sticky

BioCardia can turn its intellectual property into cash through licensing and collaboration fees, with partners paying upfront to use its cell-therapy and delivery-platform know-how. In biotech, those fees are a key non-dilutive funding source, since they can support R&D without issuing more shares.

• Upfront cash lowers equity dilution.

• Partner deals can add milestone income.

• Royalties can scale with sales.

Milestone and development payments can add non-dilutive cash when BioCardia, Inc. hits trial or regulatory steps, such as first-patient dosed, phase readouts, IND clearance, or FDA review events. For platform deals, they matter because the partner pays for execution, not just product sales.

• Trial progress triggers cash
• Regulatory wins unlock cash
• Best fit for platform tech